Immunology
8 drugs are in development for Atopic Dermatitis.
- Companies
- 7
- Clinical trials
- 108
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Atopic Dermatitis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(3)
| Drug | Company |
|---|---|
| ADX-248 | Aldeyra Therapeutics, Inc. (ALDX) |
| ATI-2138 | Aclaris Therapeutics, Inc. (ACRS) |
| prn473 | Principia Biopharma Inc. (PRNB) |
Phase 1(1)
| Drug | Company |
|---|---|
| star-0310 | BIOCRYST PHARMACEUTICALS INC (BCRX) |
Preclinical(1)
| Drug | Company |
|---|---|
| IMC-U120AI | Immunocore Holdings plc (IMCR) |
About this indication
Atopic Dermatitis context
Immunology·MeSH: Dermatitis, Atopic (D003876)
Also known as: Atopic Eczema, Atopic Neurodermatitis, Disseminated Neurodermatitis
Prevalence
7000.0 / 100K
Incidence
800.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Atopic Dermatitis?
BioSniper tracks 8 drugs in development for Atopic Dermatitis across 7 companies.
How many clinical trials target Atopic Dermatitis?
There are 108 clinical trials targeting Atopic Dermatitis tracked by BioSniper.
What is the prevalence of Atopic Dermatitis?
The estimated prevalence of Atopic Dermatitis is approximately 7000.0 per 100,000 population.